Nasdaq: ARDX

Ardelyx, Inc.

Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The company's molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. The company's non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure.